New antibody could help kidney transplant patients avoid rejection
NCT ID NCT01780844
Summary
This study tested whether a new antibody drug called ASKP1240 could help prevent organ rejection after kidney transplantation. Researchers compared the new treatment to standard anti-rejection medications in 149 patients who received new kidneys. The goal was to see if the new approach could control rejection while potentially reducing side effects from standard medications.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KIDNEY TRANSPLANTATION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Site US10001
Dallas, Texas, 75246, United States
-
Site US10002
Fort Worth, Texas, 76104, United States
-
Site US10003
San Francisco, California, 94143, United States
-
Site US10004
San Francisco, California, 94115, United States
-
Site US10005
Madison, Wisconsin, 53792, United States
-
Site US10006
Birmingham, Alabama, 35233, United States
-
Site US10007
Atlanta, Georgia, 30322, United States
-
Site US10008
Los Angeles, California, 90057, United States
-
Site US10009
Cincinnati, Ohio, 45267, United States
-
Site US10010
Chicago, Illinois, 60612, United States
-
Site US10012
Charleston, South Carolina, 29425, United States
-
Site US10013
Aurora, Colorado, 80045, United States
-
Site US10014
Baltimore, Maryland, 21201, United States
-
Site US10015
Lexington, Kentucky, 40536, United States
-
Site US10016
Durham, North Carolina, 27710, United States
-
Site US10017
Ann Arbor, Michigan, 48109, United States
-
Site US10018
Chicago, Illinois, 60612, United States
-
Site US10019
The Bronx, New York, 10467, United States
-
Site US10020
Charlottesville, Virginia, 22908, United States
-
Site US10021
Palo Alto, California, 94304, United States
-
Site US10022
Livingston, New Jersey, 07039, United States
-
Site US10023
New York, New York, 10065, United States
-
Site US10024
Phoenix, Arizona, 85054, United States
-
Site US10025
St Louis, Missouri, 63110, United States
-
Site US10026
Greenville, North Carolina, 27834, United States
-
Site US10027
Harrisburg, Pennsylvania, 17011, United States
-
Site US10028
Memphis, Tennessee, 38104, United States
-
Site US10029
Houston, Texas, 77030, United States
-
Site US10030
San Diego, California, 92123, United States
-
Site US10031
Buffalo, New York, 14215, United States
-
Site US10032
Cleveland, Ohio, 44195, United States
-
Site US10033
Salt Lake City, Utah, 84132, United States
-
Site US10034
New York, New York, 10029, United States
-
Site US10035
Nashville, Tennessee, 37232-4750, United States
-
Site US10036
Chapel Hill, North Carolina, 27599, United States
-
Site US10037
Chicago, Illinois, 60637, United States
-
Site US10038
Pittsburgh, Pennsylvania, 15213, United States
-
Site US10040
Cleveland, Ohio, 44106, United States
-
Site US10041
Augusta, Georgia, 30912, United States
-
Site US10042
Charlotte, North Carolina, 28203, United States
-
Site US10044
Houston, Texas, 77030, United States
-
Site US10045
New Orleans, Louisiana, 70112, United States
Conditions
Explore the condition pages connected to this study.